The development of therapies for Parkinson’s disease should have been a triumph long ago for medical science. Degeneration of dopaminergic nerves in the central nervous system (CNS) was identified as a key process in the condition; drugs, such as levodopa, that alleviate symptoms were identified back in the 1960s; and high-profile charities were set up to support patients and impel research into new therapeutic discoveries.
It comes as some surprise, therefore, that in past decades attempts to develop new therapies were more or less frustrating experiences, really useful biological markers to help assess the progression...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?